HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer | Scientific Reports
商品説明・詳細
送料・お届け
商品情報
HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer | Scientific Reports,Frontiers | Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma,674KB,Androgen receptor activity in T cells limits checkpoint blockade efficacy | Nature,Complement receptor CD46 co-stimulates optimal human CD8+ T cell effector function via fatty acid metabolism | Nature Communications